Twitter-Delivered CME/CE on
Oncology from @onc_ce

Clinical trial data now exit the research facility and enter the practice landscape at unprecedented speed and volume, and the arrival of COVID-19 has not slowed this rapid flow of information. In fact, the pandemic has shifted the release of data to even more accessible digital formats. At this point, clinicians who manage cancer and who hope to stay current and apply new research to their daily practice cannot do so on their own; they benefit from an expert’s interpretation and distillation of data as they carry new information from conference to bedside. The need for distilled information presented in an applicable format has risen faster than ever.

 

The heterogeneity seen in various tissue tumor types reveals a need for ever-more individualized approaches that targets molecular subtype, genetic mutations, and immunological profile for each patient. Our accredited tweetorial feed, with each program authored by international experts, provides a forum for interaction, communication, and education for all healthcare providers with an interest in cancer.  

Our Tweetorials

Your new source for free CE/CME via Twitter!
Each program provides 0.5hr – 1.0hr credit for physicians, pharmacists, and nurses.

Cancer-Associated VTE

1) Welcome to a new #accredited #tweetorial on a 🗝️ topic in #cancer care: #VTE (#DVT and #PE). Cancer patients are at ⬆️risk from their disease,...

@ONC_CE on Twitter

Your only source for ACCREDITED SoMe-delivered serialized professional oncology education. Physicians, nurses, pharmacists–come one, come all!

On Twitter at @onc_ce, we present a series of tweetorials, Twitter-delivered case studies, and Twitter Journal Clubs, each accredited for 0.5hr – 1.0hr CE/CME.  Programs are presented by expert faculty in engaging and fully interactive format.  Our unique program harnesses the reach, up-to-the-minute currency, and accessibility of social media to deliver a constant flow of accredited, interactive, expert-delivered educational programs to a multidisciplinary and interprofessional audience of engaged clinicians.

Completed programs appear “unrolled” on this webpage, but to maximize the learning value of these innovative programs, please follow @onc_ce.

Final analysis from the KN177 trial of first-line pembro vs chemo in MSI-H mCRC.
Impressive survival curves: if you don’t progress to pembro by 12m, there’s little likelihood to progress in subsequent years. Median OS not reached. Some cured?@pashtoonkasi
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00197-8/fulltext

@OncoAlert @stolaney1 @IlanaSchlam Would love to see if we could find a regimen with less intense chemo with immuno benefit.

Plat/taxane -AC is tough for many.

Load More...